Cystic fibrosis related diabetes – causes, impact on health and management of patients
DOI:
https://doi.org/10.1002/edn.256Keywords:
cystic fibrosis, cystic-fibrosis-related diabetes (CFRD), cystic fibrosis transmembrane conductance regulator protein (CFTR)Abstract
AbstractCystic fibrosis is the commonest, life-threatening recessively inherited disease in the Caucasian population. The disease process which primarily affects the lungs also damages both exocrine and endocrine pancreatic function. With increasing survival, cystic fibrosis-related diabetes is becoming more prevalent increasing from 15% of adolescents with cystic fibrosis to 50% of adults. Impaired glucose tolerance is also common. Insulin secretion gradually decreases over time. Insulin resistance also occurs and can vary dramatically with intercurrent illness. Even mild degrees of hyperglycaemia adversely affect nutritional status and lung function. Good blood glucose control improves nutritional status and lung function. Cystic fibrosis-related diabetes develops insidiously, so that annual screening is recommended, ideally by oral glucose tolerance testing. HbA1c is not sufficiently sensitive to identify early abnormalities in glucose tolerance. Aims of managing cystic fibrosis-related diabetes are to relieve symptoms, maintain normal body weight and growth, improve lung function and improve life expectancy. Insulin is the treatment of choice and the regimen should be tailored to the individual. Initially, only rapid-acting insulin with the main meal may be necessary, but as insulin secretion diminishes, a full basal-bolus regimen becomes necessary. Individuals with cystic fibrosis struggle to consume sufficient calories, so that a high calorie, high fat diet is usually appropriate. Supplemental enteral nutrition, with matching insulin administration, is frequently required. Special situations, including pregnancy, require specific management. The psychological impact of cystic fibrosis-related diabetes on the individual is enormous. Successful management requires support from a multi-disciplinary team with the necessary specialist knowledge and skills.
Downloads
References
Konrad K, et al. Cystic fibrosis-related dia-betes compared with type 1 and type 2 dia-betes in adults. Diabetes Metab Res Rev 2013;29:568–75.
Moran A, et al. Cystic fibrosis-related dia-betes: current trends in prevalence, inci-dence and mortality. Diabetes Care 2009;32:1626–31.
Street ME, et al. Insulin production and resistance in cystic fibrosis: effect of age, disease activity and genotype. J Endocrinol Invest 2012;35:246–53.
Ode KL, Moran A. New insights into cysticfibrosis-related diabetes in children. Lancet Diabetes Endocrinol 2013;1:52–8.
Blackman SM, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009;52:1858–65.
Blackman SM, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 2013;62:3627–35.
Alicandro G, et al. Insulin secretion, nutri-tional status and respiratory function in cystic fibrosis patients with normal glucose tolerance. Clin Nutr 2012;31:118–23.
Brodsky J, et al. Elevation of 1-hour plasmaglucose during oral glucose tolerance test-ing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011;34:292–5.
Rolon MA, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of pre-diabetes and effects of insulin therapy. Acta Paediatr 2001;90:860–7.
Lanng S, et al. Influence of the develop-ment of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992;151:686–7.
Finkelstein SM, et al. Diabetes mellitus asso-ciated with cystic fibrosis. J Pediatr 1988;112:373–7.
Swartz LM, Laffel LM. A teenage girl with cystic fibrosis-related diabetes, diabetic ketoacidosis and cerebral edema. Pediatr Diabetes 2008;9:426–30.
UK Cystic Fibrosis Trust Diabetes Working Group. Management of cystic fibrosis related diabetes mellitus. Cystic Fibrosis Trust 2004. www.cysticfibrosis.org.
Moran A, et al. CFRD guidelines commit-tee. Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes: A position state-ment of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697–708.
Smyth AR, et al. European Cystic Fibrosis Society Standards of Care: Best Practice Guidelines. J Cyst Fibros 2014;1351:523–42.
Middleton PG, et al. Australian standards of care for cystic fibrosis-related diabetes. Respirology 2013;Dec 23. Doi:10.1111/ resp.12227.
Waugh N, et al. Screening for cystic fibrosis-related diabetes: a systematic review. Health Technol Assess 2012; 16: iii-iv, 1–179.
O'Riordan SM, et al. Validation of continu-ous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009;32:1020–2.
Bismuth E, et al. Glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010;11:487–92.
Ode KL, et al. Oral glucose tolerance test-ing in children with cystic fibrosis. Pediatr Diabetes 2010;11:487–92.
Koch C, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 200-132: 343–50.
Adler Al, et al. Hyperglycaemia and death in cystic fibrosis-related diabetes. Diabetes Care 2011;34:1577–8.
Chamnan P, et al. Diabetes as a determi-nant of mortality in cystic fibrosis. Diabetes Care 2010;33:311–6.
Welsh L, et al. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatr Pulmonol 2013; Oct 31 doi 10.1002/ppu 122–946.
Kerem E, et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J 2014;43:125–33.
Moran A, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes with-out fasting hyperglycaemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32:1783–8.
Mozzillo E, et al. One-year glargine treat-ment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derange-ments. Pediatr Diabetes 2009;10:162–7.
Dobson L, et al. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Disease Child 2002;87:430–1.
Andersen HU, et al. Cystic fibrosis-related diabetes: the presence of microvascular complications. Diabetes Care 2006;29:2660–3.
Schwarzenberg SJ, et al. Microvascular com-plications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056–61.
Ramsey BW, et al. Nutritional Assessment and management in cystic fibrosis: a con-sensus report. The Consensus Committee: Am J Clin Nutr 1992; 108–16.
Morrison J M, et al. Energy intakes and losses in cystic fibrosis. J Hum Nutr Diet 1994;7:39–46.
Sinaasappel M, et al. Nutrition in patients with cystic fibrosis: A European consensus. J Cyst Fibrosis 2002;1:67–91.
Nutritional Management of Cystic Fibrosis. CF Nutrition Working Group London: CF Trust 2002.
White H, et al. Enteral tube feeding in adults with cystic fibrosis; patient choice and impact on long term outcomes. J Cyst Fibrosis 2013;12:616–22.
Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis related diabetes. Cochrane Database Syst Rev 2013;7: CD004730.
Hameed S, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child 2012;97:464–7.
Kessler L, et al. Combined pancreatic islets-lung transplantation in cystic fibrosis-related diabetes: case reports. Transplant Proc 2010;42:4338–40.
Bandsma RH, et al. Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicentre experience. J Cyst Fibros 2014; in press.
Moran A, et al. Pancreatic endocrine function in cystic fibrosis. J Pediatric 1991;118:715–23.
Yahiaoui Y, et al. Renal involvement in cystic fibrosis: disease spectrum and clini-cal relevance. Clin J Am Soc Nephrol 2009;4:921–8.
Edenborough FP, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008;7:52–532.
Valour F, et al. Outcome of cystic fibrosis-related diabetes two years after lung trans-plantation. Respiration 2013;86:32–8.
Ye X, et al. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. Clin Transplant 2011;25:583–95.
Collins S, Reynolds F. How do adults with cystic fibrosis cope following a diagnosis of diabetes? J Adv Nurs 2008;64:478–87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Copyright © 2011 FEND.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
